News

Image source: The Motley Fool.

Sarepta Therapeutics (NASDAQ: SRPT)Q2 2024 Earnings CallAug 07, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

By no means were Amgen's (NASDAQ: AMGN) second-quarter numbers "bad." Revenue for most of its core drugs was up year over year, and the slight earnings dip is the predictable result of rising

Dividend growth investing is an excellent strategy for any long-term investor. It involves buying and holding companies that pay and raise their dividends year after year. Investors benefit from

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q2 2024 Earnings CallAug 06, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical maker, were climbing today after the company reported better-than-expected results in its second-quarter earnings report and raised

Every corporation will face challenges and setbacks -- which will sometimes sink its stock price. That's not a good reason for long-term investors to jump ship unless, of course, there's a

July 25 was a difficult day for DexCom (NASDAQ: DXCM) shareholders, with the company's second-quarter earnings release crashing the stock by 40%. To make matters worse, at the moment it's unclear

The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4%

Except for the last several days, the past 12 months have been pretty good for stocks across the board and especially successful for Vertex Pharmaceuticals (NASDAQ: VRTX). Shares of the biotech

When it comes to investing in the right companies for your portfolio, you need to ensure you select businesses that you understand and have the competitive advantages, financials, and leadership to

Industry insiders often have perspectives that are invaluable for investors to learn. In that vein, AstraZeneca's (NASDAQ: AZN) CEO, Pascal Soriot, recently made some interesting remarks during the

Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price

There are plenty of excellent reasons to invest in dividend stocks, including the fact that only rock-solid companies can afford to sustain payout increases for a long time. When you put your money

Few healthcare companies are more famous than Johnson & Johnson (NYSE: JNJ). The pharmaceutical giant earned its stature in the industry thanks to its incredible innovative abilities and a business

Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro

The biotech Amgen (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate. The drugmaker

Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.

However, Vertex

Johnson & Johnson (NYSE: JNJ) is one of the top healthcare companies in the world. Last year, it spun off its consumer health business to focus on growing other parts of its operations, which

Pfizer (NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of